Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Shared pathways: death receptors and cytotoxic drugs in cancer therapy.
Peták I, Houghton JA. Peták I, et al. Pathol Oncol Res. 2001;7(2):95-106. doi: 10.1007/BF03032574. Pathol Oncol Res. 2001. PMID: 11458271 Review.
Cystein cathepsin and Hsp90 activities determine the balance between apoptotic and necrotic cell death pathways in caspase-compromised U937 cells.
Imre G, Dunai Z, Petak I, Mihalik R. Imre G, et al. Among authors: petak i. Biochim Biophys Acta. 2007 Oct;1773(10):1546-57. doi: 10.1016/j.bbamcr.2007.07.003. Epub 2007 Jul 19. Biochim Biophys Acta. 2007. PMID: 17707089
Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.
Tímár J, Ladányi A, Peták I, Jeney A, Kopper L. Tímár J, et al. Among authors: petak i. Pathol Oncol Res. 2003;9(1):49-72. doi: 10.1007/BF03033715. Epub 2003 Apr 18. Pathol Oncol Res. 2003. PMID: 12704448 Review.
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K, Székely-Szüts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhász H, Dominici M, Spano C, Luca Cervo G, Conte P, Houghton JA, Mihalik R, Kopper L, Peták I. Nagy K, et al. Among authors: petak i. Pathol Oncol Res. 2006;12(3):133-42. doi: 10.1007/BF02893359. Epub 2006 Sep 23. Pathol Oncol Res. 2006. PMID: 16998592
Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE. O'Kane HF, et al. Among authors: petak i. J Urol. 2006 Feb;175(2):432-8. doi: 10.1016/S0022-5347(05)00160-6. J Urol. 2006. PMID: 16406966 Review.
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M. Grisendi G, et al. Among authors: petak i. Cancer Res. 2010 May 1;70(9):3718-29. doi: 10.1158/0008-5472.CAN-09-1865. Epub 2010 Apr 13. Cancer Res. 2010. PMID: 20388793
When injected i.v. or s.c. into mice, AD-MSC armed with TRAIL localized into tumors and mediated apoptosis without significant apparent toxicities to normal tissues. ...
When injected i.v. or s.c. into mice, AD-MSC armed with TRAIL localized into tumors and mediated apoptosis without significant appare …
P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells.
Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA. Geller JI, et al. Among authors: petak i. Cancer Res. 2004 Sep 1;64(17):6296-303. doi: 10.1158/0008-5472.CAN-04-0863. Cancer Res. 2004. PMID: 15342418
Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J, Petak I, Szucs KS, Nagy K, Tillman DM, Houghton JA. Geller J, et al. Among authors: petak i. Clin Cancer Res. 2003 Dec 15;9(17):6504-15. Clin Cancer Res. 2003. PMID: 14695155
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, Houghton JA. Schwartzberg LS, et al. Among authors: petak i. Clin Cancer Res. 2002 Aug;8(8):2488-98. Clin Cancer Res. 2002. PMID: 12171874 Clinical Trial.
Based on results from our preclinical studies we designed a Phase I trial combining FUra (370 mg/m2) and LV (200 mg/m2), i.v. bolus daily x 5 days, with escalating doses of IFN-gamma (10-100 micro g/m2) s.c. on days 1, 3, and 5, every 28 days. ...On the basis of the …
Based on results from our preclinical studies we designed a Phase I trial combining FUra (370 mg/m2) and LV (200 mg/m2), i.v. …
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, Billups CA, Panetta JC, Stewart CF. Turner PK, et al. Among authors: petak i. Cancer Chemother Pharmacol. 2004 Mar;53(3):253-60. doi: 10.1007/s00280-003-0723-8. Epub 2003 Nov 28. Cancer Chemother Pharmacol. 2004. PMID: 14648016 Clinical Trial.
70 results
Jump to page
Feedback